• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

共病性情绪、焦虑和物质使用障碍的药物治疗

Pharmacotherapy of comorbid mood, anxiety, and substance use disorders.

作者信息

Brady Kathleen T, Verduin Marcia L

机构信息

Institute of Psychiatry, Medical University of South Carolina, Charleston, South Carolina 29425, USA.

出版信息

Subst Use Misuse. 2005;40(13-14):2021-41, 2043-8. doi: 10.1080/10826080500294924.

DOI:10.1080/10826080500294924
PMID:16282091
Abstract

Mood and anxiety disorders commonly co-occur with substance use disorders. Exploration of the neurobiology of substance use disorders and mood and anxiety disorders have found that the neural circuitry in mood, anxiety, and substance use disorders is clearly overlapping. These discoveries have encouraged the exploration of a number of pharmacotherapeutic agents in the treatment of co-occurring mood, anxiety, and substance use disorders. In this article, recent data on the pharmacotherapeutic treatment of mood and anxiety disorders in individuals with substance use disorders are reviewed. Some of the barriers to the use of pharmacotherapy in individuals with substance use disorders are discussed.

摘要

情绪和焦虑障碍通常与物质使用障碍同时出现。对物质使用障碍以及情绪和焦虑障碍的神经生物学研究发现,情绪、焦虑和物质使用障碍中的神经回路明显重叠。这些发现促使人们探索多种药物治疗剂来治疗同时出现的情绪、焦虑和物质使用障碍。在本文中,我们综述了有关物质使用障碍患者情绪和焦虑障碍药物治疗的最新数据。还讨论了在物质使用障碍患者中使用药物治疗的一些障碍。

相似文献

1
Pharmacotherapy of comorbid mood, anxiety, and substance use disorders.共病性情绪、焦虑和物质使用障碍的药物治疗
Subst Use Misuse. 2005;40(13-14):2021-41, 2043-8. doi: 10.1080/10826080500294924.
2
The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders.焦虑症共病对难治性双相情感障碍的影响。
Depress Anxiety. 2008;25(2):91-7. doi: 10.1002/da.20279.
3
Anxious depression.焦虑性抑郁
J Clin Psychiatry. 1998;59 Suppl 18:10-7.
4
Comorbidity of mood and anxiety disorders.情绪障碍与焦虑障碍的共病情况。
Depress Anxiety. 2000;12 Suppl 1:69-76. doi: 10.1002/1520-6394(2000)12:1+<69::AID-DA9>3.0.CO;2-K.
5
Anxiety disorders in schizophrenia.精神分裂症中的焦虑障碍
Compr Psychiatry. 2004 Nov-Dec;45(6):460-8. doi: 10.1016/j.comppsych.2004.07.009.
6
Management of comorbid anxiety and depression.共病焦虑和抑郁的管理。
J Clin Psychiatry. 1995;56 Suppl 2:10-3.
7
Bipolar disorder and comorbid anxiety disorders in children and adolescents.儿童和青少年的双相情感障碍及共病焦虑症
J Clin Psychiatry. 2006;67 Suppl 1:16-20.
8
The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders.加拿大情绪与焦虑治疗网络(CANMAT)工作组关于心境障碍合并焦虑障碍患者管理的建议。
Ann Clin Psychiatry. 2012 Feb;24(1):6-22.
9
Three-year incidence and predictors of first-onset of DSM-IV mood, anxiety, and substance use disorders in older adults: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions.DSM-IV 心境、焦虑和物质使用障碍在老年人中的首发 3 年发生率及预测因素:来自国家酒精相关条件流行病学调查第 2 波的结果。
J Clin Psychiatry. 2011 Feb;72(2):144-55. doi: 10.4088/JCP.09m05618gry.
10
Social anxiety disorder: comorbidity and its implications.社交焦虑障碍:共病情况及其影响。
J Clin Psychiatry. 2001;62 Suppl 1:17-23; discussion 24.

引用本文的文献

1
Comorbidities of Major Depressive Disorder and Bipolar Disorders in Patients with Substance Use Disorder in Iran Psychiatric Hospital: A Cross-sectional Study.伊朗精神病医院物质使用障碍患者中重度抑郁症和双相情感障碍的共病情况:一项横断面研究
Med J Islam Repub Iran. 2023 Feb 7;37:3. doi: 10.47176/mjiri.37.3. eCollection 2023.
2
Depression and Its Phytopharmacotherapy-A Narrative Review.抑郁及其植物药治疗——一个叙述性综述。
Int J Mol Sci. 2023 Mar 1;24(5):4772. doi: 10.3390/ijms24054772.
3
Network Analysis and Precision Rehabilitation for the Post-concussion Syndrome.
脑震荡后综合征的网络分析与精准康复
Front Neurol. 2019 May 29;10:489. doi: 10.3389/fneur.2019.00489. eCollection 2019.
4
Was Hawan Designed to Fight Anxiety-Scientific Evidences?Hawan 旨在对抗焦虑吗?科学证据如何?
J Relig Health. 2020 Feb;59(1):505-521. doi: 10.1007/s10943-016-0345-1.
5
Treatment of co-occurring anxiety disorders and substance use disorders.共病焦虑症和物质使用障碍的治疗。
Harv Rev Psychiatry. 2015 Mar-Apr;23(2):99-111. doi: 10.1097/HRP.0000000000000058.
6
Behavioral effects of bidirectional modulators of brain monoamines reserpine and d-amphetamine in zebrafish.脑单胺双向调节剂利血平和 d-苯丙胺对斑马鱼的行为影响。
Brain Res. 2013 Aug 21;1527:108-16. doi: 10.1016/j.brainres.2013.06.033. Epub 2013 Jul 1.
7
Integrated treatment of substance use and psychiatric disorders.物质使用和精神障碍的综合治疗。
Soc Work Public Health. 2013;28(3-4):388-406. doi: 10.1080/19371918.2013.774673.
8
Anxiety and alcohol use disorders: comorbidity and treatment considerations.焦虑症与酒精使用障碍:共病情况及治疗考量
Alcohol Res. 2012;34(4):414-31.
9
The serotonin 2C receptor antagonist SB 242084 exhibits abuse-related effects typical of stimulants in squirrel monkeys.血清素 2C 受体拮抗剂 SB 242084 在松鼠猴中表现出典型的兴奋剂类药物的滥用相关效应。
J Pharmacol Exp Ther. 2012 Sep;342(3):761-9. doi: 10.1124/jpet.112.195156. Epub 2012 Jun 8.
10
Exploring the comorbidity of anxiety and substance use disorders.探讨焦虑和物质使用障碍的共病现象。
Curr Psychiatry Rep. 2012 Jun;14(3):176-81. doi: 10.1007/s11920-012-0264-0.